Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 3
2015 3
2016 3
2017 7
2018 3
2019 5
2020 6
2021 4
2022 1
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.
Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, Böhringer S, Cambon-Thomsen A, Cecchin E, Cheung KC, Deneer VH, Dupui M, Ingelman-Sundberg M, Jonsson S, Joefield-Roka C, Just KS, Karlsson MO, Konta L, Koopmann R, Kriek M, Lehr T, Mitropoulou C, Rial-Sebbag E, Rollinson V, Roncato R, Samwald M, Schaeffeler E, Skokou M, Schwab M, Steinberger D, Stingl JC, Tremmel R, Turner RM, van Rhenen MH, Dávila Fajardo CL, Dolžan V, Patrinos GP, Pirmohamed M, Sunder-Plassmann G, Toffoli G, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium. Swen JJ, et al. Lancet. 2023 Feb 4;401(10374):347-356. doi: 10.1016/S0140-6736(22)01841-4. Lancet. 2023. PMID: 36739136 Clinical Trial.
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer.
Cremolini C, Antoniotti C, Stein A, Bendell J, Gruenberger T, Rossini D, Masi G, Ongaro E, Hurwitz H, Falcone A, Schmoll HJ, Di Maio M. Cremolini C, et al. Among authors: ongaro e. J Clin Oncol. 2020 Aug 20:JCO2001225. doi: 10.1200/JCO.20.01225. Online ahead of print. J Clin Oncol. 2020. PMID: 32816630 Free article.
Liquid biopsy in colorectal cancer: Onward and upward.
Torresan S, de Scordilli M, Bortolot M, Di Nardo P, Foltran L, Fumagalli A, Guardascione M, Ongaro E, Puglisi F. Torresan S, et al. Among authors: ongaro e. Crit Rev Oncol Hematol. 2024 Feb;194:104242. doi: 10.1016/j.critrevonc.2023.104242. Epub 2023 Dec 20. Crit Rev Oncol Hematol. 2024. PMID: 38128627 Review.
Immunotherapy for colorectal cancer: where are we heading?
Basile D, Garattini SK, Bonotto M, Ongaro E, Casagrande M, Cattaneo M, Fanotto V, De Carlo E, Loupakis F, Urbano F, Negri FV, Pella N, Russano M, Brunetti O, Scartozzi M, Santini D, Silvestris N, Casadei Gardini A, Puzzoni M, Calvetti L, Cardarelli N, Aprile G. Basile D, et al. Among authors: ongaro e. Expert Opin Biol Ther. 2017 Jun;17(6):709-721. doi: 10.1080/14712598.2017.1315405. Epub 2017 Apr 13. Expert Opin Biol Ther. 2017. PMID: 28375039 Free article. Review.
Preoperative treatments in borderline resectable and locally advanced pancreatic cancer: Current evidence and new perspectives.
de Scordilli M, Michelotti A, Zara D, Palmero L, Alberti M, Noto C, Totaro F, Foltran L, Guardascione M, Iacono D, Ongaro E, Fasola G, Puglisi F. de Scordilli M, et al. Among authors: ongaro e. Crit Rev Oncol Hematol. 2023 Jun;186:104013. doi: 10.1016/j.critrevonc.2023.104013. Epub 2023 Apr 26. Crit Rev Oncol Hematol. 2023. PMID: 37116817 Review.
NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome.
Michelotti A, de Scordilli M, Palmero L, Guardascione M, Masala M, Roncato R, Foltran L, Ongaro E, Puglisi F. Michelotti A, et al. Among authors: ongaro e. Cells. 2021 Aug 9;10(8):2034. doi: 10.3390/cells10082034. Cells. 2021. PMID: 34440803 Free PMC article. Review.
Sarcopenia in gastric cancer: when the loss costs too much.
Ongaro E, Buoro V, Cinausero M, Caccialanza R, Turri A, Fanotto V, Basile D, Vitale MG, Ermacora P, Cardellino GG, Nicoletti L, Fornaro L, Casadei-Gardini A, Aprile G. Ongaro E, et al. Gastric Cancer. 2017 Jul;20(4):563-572. doi: 10.1007/s10120-017-0722-9. Epub 2017 May 5. Gastric Cancer. 2017. PMID: 28477106 Free article. Review.
Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle.
Gerratana L, Bonotto M, Bozza C, Ongaro E, Fanotto V, Pelizzari G, Puglisi F. Gerratana L, et al. Among authors: ongaro e. Expert Opin Biol Ther. 2017 Mar;17(3):365-374. doi: 10.1080/14712598.2017.1282944. Epub 2017 Jan 30. Expert Opin Biol Ther. 2017. PMID: 28092723 Review.
Immunotherapy for gastric cancers: emerging role and future perspectives.
Bonotto M, Garattini SK, Basile D, Ongaro E, Fanotto V, Cattaneo M, Cortiula F, Iacono D, Cardellino GG, Pella N, Fasola G, Antonuzzo L, Silvestris N, Aprile G. Bonotto M, et al. Among authors: ongaro e. Expert Rev Clin Pharmacol. 2017 Jun;10(6):609-619. doi: 10.1080/17512433.2017.1313113. Epub 2017 Apr 10. Expert Rev Clin Pharmacol. 2017. PMID: 28349740 Review.
38 results